Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05903937 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

Study acronym: HAITILS-PHP
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 years later Dec 31, 2024 → Dec 31, 2029
See other at-risk trials from Vastra Gotaland Region

Record History

  1. Primary completion pushed from Dec 31, 2024 to Dec 31, 2029
    • Start date: Dec 31, 2023 to Jan 31, 2027
    • Study completion pushed from Dec 31, 2029 to Dec 31, 2031
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Vastra Gotaland Region
139 trials monitored
See 11 trials at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma
Trial Details
NCT Number NCT05903937
Lead Sponsor Vastra Gotaland Region
Conditions
(from sponsor)		 Uveal Melanoma, Metastatic Cutaneous Melanoma
Related terms Melanoma, Uveal Melanoma
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov